Clinical trials: Esophageal Reflux
Gastroesophageal Reflux, Gastric Ulcer
Safety of Rabeprazole in Patients Under Multiple Treatments
The purpose of this study is to evaluate the safety of rabeprazole 20mg/day in polymedicated patients and to examine the necessity of adjusted dosage in both therapies (rabeprazole and concomitant drug).
- Trial name
- NCT00511745
- Testing
- Rabeprazol
- Volunteers
- 2,157 people
- Sponsor
- Janssen-Cilag, S.A.
Chronic Posterior Laryngitis (CPL)
Chronic Posterior Laryngitis With Suspected Laryngopharyngeal Reflux
This study looks at how effective acid suppression therapy is on symptoms associated with chronic posterior laryngitis (CPL) in patients with documented pharyngeal acid reflux.
- Trial name
- NCT00628667
- Testing
- Esomeprazole
- Volunteers
- 120 people
- Sponsor
- AstraZeneca
Refractory Reflux Esophagitis
Quality of Life in New Treatable Therapy as Rabeprazole Option for Refractory Reflux Esophagitis
To investigate the efficacy and safety of PARIET twice daily (b.i.d.) in patients with Proton Pump Inhibitor-resistant reflux esophagitis
- Trial name
- NCT01321567
- Testing
- rabeprazole sodium
- Where
- 447 sites in Japan
- Volunteers
- 2,157 people
- Sponsor
- Eisai Co., Ltd.
Erosive Esophagitis
Clinical Trial to Assess the Efficacy and Safety of YYD601 in the Treatment of Esophageal Reflux Disease (ERD)
A randomized, double-blind, double-dummy, active comparator, multi-centers, non-inferiority design clinical trial to assess the efficacy and safety of YYD601 in ERD patients (phase 3).
- Trial name
- NCT03943992
- Testing
- YYD601 40mg, Nexium 40mg
- Where
- South Korea
- Volunteers
- 170 people
- Sponsor
- Yooyoung Pharmaceutical Co., Ltd.
GERD
Clinical Trial to Assess the PK/PD of YYD601 20mg After Oral Administration if Healthy Adult Subjects (Phase1)
Clinical Trial to Assess the PK/PD of YYD601 20mg After Oral Administration if Healthy Adult Subjects (Phase1)
- Trial name
- NCT03985319
- Testing
- YYD601 20mg, Nexium tab 20mg
- Where
- South Korea
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Yooyoung Pharmaceutical Co., Ltd.
Esophagitis, Reflux, Esophagitis, Peptic
Efficacy and Safety of Dexlansoprazole MR Compared to Placebo on Maintaining Healing in Subjects With Healed Erosive Esophagitis
The purpose of this study is to assess the ability of once-daily (QD) treatment with dexlansoprazole modified release (MR) 30 mg and 60 mg or placebo in maintaining healing of erosive esophagitis (EE).
- Trial name
- NCT00321737
- Testing
- Dexlansoprazole MR
- Where
- 98 sites in United States, Australia and 6 more
- Volunteers
- 445 people
- Sponsor
- Takeda
Gastroesophageal Reflux
German PMS Trial (AWB) to Evaluate Therapy in Reflux Disease and NSAR-Symptoms
This PMS study had the objective to evaluate under ordinary medical care conditions the efficacy and tolerability of esomeprazole in patients who where treated by general practitioners and internists.
- Trial name
- NCT00567021
- Volunteers
- 67,130 people
- Sponsor
- AstraZeneca
End Stage Renal Failure on Dialysis
Argyle Safety Fistula Cannula With Anti-reflux Valve Clinical Study
The purpose of the investigation is to confirm the safety and performance of the Argyle™ Safety Fistula Cannula with Anti-reflux Valve for hemodialysis treatment.
- Trial name
- NCT05927532
- Testing
- Argyle Safety Fistula Cannula with Anti-Reflux Valve
- Where
- 3 sites in United States
- Volunteers
- 40 people
- Sponsor
- Mozarc Medical US LLC
GERD (Gastroesophageal Reflux Disease)
Study to Evaluate the Effect of Food on the Pharmacokinetics and Pharmacodynamics Characteristics in Healthy Adult Volunteers
A Randomized, Open-label, Oral in healthy volunteers
- Trial name
- NCT07364838
- Testing
- DW4421
- Where
- South Korea
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Daewon Pharmaceutical Co., Ltd.
GERD
LIFE NIS, GERD-Patients - Evaluation of Burden of Disease Determined by GERD Impact Scale (GIS)
Evaluate burden of disease in Patients with newly occurred upper GI symptoms related to GERD (symptom frequency \& severity, QoL, lifestyle modifications, self-medication) - baseline data according to GERD impact scale presenting…
- Trial name
- NCT00567619
- Where
- Austria
- Volunteers
- 900 people
- Sponsor
- AstraZeneca
GERD (Gastroesophageal Reflux Disease)
An Observational Study to Evaluate the Efficacy and Safety of K-CAB Tab./K-CAB ODT(Tegoprazan) in GERD Patients
This study aims to evaluate the status of AE and improvement effect of K-CAB Tab/K-CAB ODT(Tegoprazan) 50mg in patients with GERD.
- Trial name
- NCT07678177
- Where
- South Korea
- Volunteers
- 5,384 people
- Sponsor
- HK inno.N Corporation
Gastroesophageal Reflux Disease
Safety and Efficacy of Dexlansoprazole Delayed-Release Capsules in Treating Symptomatic Non-Erosive Gastroesophageal Reflux Disease in Adolescents
The purpose of this study was to assess the safety and effectiveness of once daily oral administration of dexlansoprazole delayed-release capsules in adolescent participants with symptomatic non-erosive gastroesophageal reflux…
- Trial name
- NCT01642602
- Testing
- Dexlansoprazole
- Where
- 64 sites in United States, Belgium and 6 more
- Volunteers
- 104 people
- Sponsor
- Takeda
Gastroesophageal Reflux, GERD
Determination of a Questionnaire After Treatment With Pantoprazole at Full Dose and Half Dose in Adult Patients With Symptoms of Acid Reflux (Gastroesophageal Reflux Disease) (BY1023/UK-506)
Gastroesophageal reflux disease (GERD) is a medical condition affecting the stomach and esophagus. GERD occurs when the lower esophageal sphincter does not close properly and stomach contents leaks back (refluxes) into the…
- Conditions
- Gastroesophageal Reflux, GERD, GORD
- Trial name
- NCT00261339
- Testing
- Pantoprazole
- Where
- 45 sites in United Kingdom
- Volunteers
- 300 people
- Sponsor
- Takeda
GERD
A Study to Compare PK and Safety of CKD-381 and D026 in Healthy Male Subjects
A Study to compare pharmacokinetics and safety of CKD-381 and D026 in healthy male subjects
- Trial name
- NCT03444402
- Testing
- CKD-381(formulation I), CKD-381(formulation II), D026(Nexium 40mg)
- Where
- South Korea
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Gastroesophageal Reflux
ADX10059 as an add-on Therapy to Proton Pump Inhibitors (PPIs) in Patients With Gastroesophageal Reflux (GERD)
The purpose of this study is to evaluate the effect of ADX10059 in patients with gastroesophageal reflux disease who are partial responders to proton pump inhibitors
- Trial name
- NCT00810485
- Testing
- ADX10059
- Where
- 40 sites in United States, France and 3 more
- Volunteers
- 298 people
- Sponsor
- Addex Pharma S.A.
Gastroesophageal Reflux Disease
Feasibility Study for Evaluating the Effect of Electrical Stimulation on Lower Esophageal Sphincter Pressure and Esophageal Acid Exposure in Patients With Gastroesophageal Reflux Disease
The EndoStim Stimulation System is an investigational device intended to improve the lower esophageal sphincter (LES) resting tone and restore LES function in individuals suffering with gastroesophageal reflux disease (GERD).
- Trial name
- NCT01578642
- Testing
- EndoStim LES Stimulation System
- Where
- Chile
- Volunteers
- 24 people
- Sponsor
- EndoStim Inc.
Mitral Valve (MV) Regurgitation
DragonFly M2 Pivotal Study
To confirm the effectiveness and safety of the DragonFly M2 Transcatheter Mitral Valve Repair System for the treatment of symptomatic moderate-to-severe (3+) or severe (4+) degenerative mitral regurgitation in high surgical risk…
- Trial name
- NCT07243197
- Testing
- DragonFly M2 Transcatheter Mitral Valve Repair System
- Where
- China
- Volunteers
- 53 people
- Sponsor
- Hangzhou Valgen Medtech Co., Ltd
Gastroesophageal Reflux
A Study of Dexlansoprazole Modified Release Formulation to Treat Night Heartburn
The purpose of this study is to determine whether Dexlansoprazole once daily (QD) is effective in treating patients with night heartburn.
- Trial name
- NCT00627016
- Testing
- Dexlansoprazole
- Where
- 43 sites in United States
- Volunteers
- 305 people
- Sponsor
- Takeda
Gastroesophageal Reflux Disease, GERD
What is the Predictive Value of the Reflux Impact Scale
Gastric distress is a common phenomenon in our society. Heartburn and regurgitation occur daily in about 7% of the adult population,weekly 14-20% pf the adults and monthly in 34-44% of adults.
- Conditions
- Gastroesophageal Reflux Disease, GERD, Heartburn, Acid Regurgitation
- Trial name
- PREDICT (NCT00536328)
- Volunteers
- 938 people
- Sponsor
- AstraZeneca
Gastroesophageal Reflux Disease, Hiatal Hernia
Transoral Incisionless Fundoplication (TIF) Registry Study for Treatment of Gastroesophageal Reflux Disease (GERD)
The study objective is to evaluate the safety and efficacy of TIF among a broad range of GERD patients treated in routine clinical practice at multiple centers across the United States.
- Trial name
- NCT01118585
- Testing
- TIF Procedure
- Where
- 14 sites in United States
- Volunteers
- 278 people
- Sponsor
- EndoGastric Solutions